Cite
Additional file 2: Table S1. of Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
MLA
Arnold, Douglas, et al. Additional File 2: Table S1. of Peginterferon Beta-1a Improves MRI Measures and Increases the Proportion of Patients with No Evidence of Disease Activity in Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the ADVANCE Randomized Controlled Trial. Jan. 2017. EBSCOhost, https://doi.org/10.6084/m9.figshare.c.3688261_d2.
APA
Arnold, D., Calabresi, P., Kieseier, B., Shifang Liu, Xiaojun You, Fiore, D., & Hung, S. (2017). Additional file 2: Table S1. of Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial. https://doi.org/10.6084/m9.figshare.c.3688261_d2
Chicago
Arnold, Douglas, Peter Calabresi, Bernd Kieseier, Shifang Liu, Xiaojun You, Damian Fiore, and Serena Hung. 2017. “Additional File 2: Table S1. of Peginterferon Beta-1a Improves MRI Measures and Increases the Proportion of Patients with No Evidence of Disease Activity in Relapsing-Remitting Multiple Sclerosis: 2-Year Results from the ADVANCE Randomized Controlled Trial,” January. doi:10.6084/m9.figshare.c.3688261_d2.